Press Releases Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Market Closed - Nyse Other stock markets 04:00:00 2024-05-03 pm EDT			5-day change	1st Jan Change
0.1749 ^USD	-4.58%		-2.24%	-19.10%

Apr. 30	In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	CI
Mar. 27	Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024	May. 02	GL
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	May. 01	AQ
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	Apr. 30	GL
Matinas BioPharma Prices $10 Million Registered Direct Offering	Apr. 03	GL
Matinas BioPharma Prices $10 Million Registered Direct Offering	Apr. 03	AQ
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	Mar. 27	GL
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	Mar. 27	AQ
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response	Mar. 25	AQ
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	Mar. 25	AQ
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	Mar. 25	GL
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	Mar. 25	AQ
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response	Mar. 22	GL
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	Mar. 22	GL
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	Mar. 22	AQ
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate, Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 27	AQ
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	GL
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	AQ
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis	Feb. 20	GL
Matinas BioPharma to Present at Biotech Showcase 2024	Jan. 03	GL
Matinas BioPharma to Present at Biotech Showcase 2024	Jan. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Press Releases

Filters